Galapagos NV (XAMS:GLPG) Total Liabilities : €1,309.6 Mil (As of Sep. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Galapagos NV Total Liabilities?

Galapagos NV's Total Liabilities for the quarter that ended in Sep. 2024 was €1,309.6 Mil.

Galapagos NV's quarterly Total Liabilities declined from Mar. 2024 (€1,466.37 Mil) to Jun. 2024 (€1,380.07 Mil) and declined from Jun. 2024 (€1,380.07 Mil) to Sep. 2024 (€1,309.63 Mil).

Galapagos NV's annual Total Liabilities declined from Dec. 2021 (€2,549.80 Mil) to Dec. 2022 (€2,208.33 Mil) and declined from Dec. 2022 (€2,208.33 Mil) to Dec. 2023 (€1,561.83 Mil).

Galapagos NV Total Liabilities Historical Data

The historical data trend for Galapagos NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Total Liabilities Chart

Galapagos NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3,192.95

3,047.38

2,549.80

2,208.33

1,561.83

Galapagos NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Liabilities	Get a 7-Day Free Trial															1,829.78	1,561.83	1,466.37	1,380.07	1,309.63

Galapagos NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Galapagos NV's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	428.223	+	(4.944	+	31.57
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1094.8	+	2.293)
	=	1,561.8

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	4357.396	-	2795.566
	=	1,561.8

Galapagos NV's Total Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	351.232	+	(7.24	+	30.904
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	917.965	+	2.291)
	=	1,309.6

Total Liabilities	=	Total Assets (Q: Sep. 2024 )	-	Total Equity (Q: Sep. 2024 )
	=	4172.202	-	2862.57
	=	1,309.6

Galapagos NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of Galapagos NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Galapagos NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (XAMS:GLPG) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GLPGF:USA GLPG:USA GLPGa:UK 0JXZ:UK GXE:Germany GXE:Germany G1LP34:Brazil GLPG:Austria

Address

Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800

Website

https://www.glpg.com

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.